Evidence map›Paper›PMID 32463402›Full record

ArticleNanoscale2020

Sequential deletion of CD63 identifies topologically distinct scaffolds for surface engineering of exosomes in living human cells.

Natalie Curley, Daniel Levy, Mai Anh Do, Annie Brown, Zachary Stickney, Gerard Marriott, Biao Lu

Open access · greenAbstract read
In one paragraph

Article in Nanoscale, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Biologics-based technologies for highly efficient and targeted RNA delivery.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Natalie CurleyDepartment of Bioengineering, Santa Clara University, 500 El Camino Real, Santa Clara, CA 95053, USA. blu2@scu.edu nduong@alumni.scu.edu dhlevy@umd.edu mdo@alumni.scu.edu akbrown@scu.edu zacstickney@gmail.com.
Daniel LevyDepartment of Bioengineering, Santa Clara University, 500 El Camino Real, Santa Clara, CA 95053, USA. blu2@scu.edu nduong@alumni.scu.edu dhlevy@umd.edu mdo@alumni.scu.edu akbrown@scu.edu zacstickney@gmail.com.
Mai Anh DoDepartment of Bioengineering, Santa Clara University, 500 El Camino Real, Santa Clara, CA 95053, USA. blu2@scu.edu nduong@alumni.scu.edu dhlevy@umd.edu mdo@alumni.scu.edu akbrown@scu.edu zacstickney@gmail.com.
Annie BrownDepartment of Bioengineering, Santa Clara University, 500 El Camino Real, Santa Clara, CA 95053, USA. blu2@scu.edu nduong@alumni.scu.edu dhlevy@umd.edu mdo@alumni.scu.edu akbrown@scu.edu zacstickney@gmail.com.
Zachary StickneyDepartment of Bioengineering, Santa Clara University, 500 El Camino Real, Santa Clara, CA 95053, USA. blu2@scu.edu nduong@alumni.scu.edu dhlevy@umd.edu mdo@alumni.scu.edu akbrown@scu.edu zacstickney@gmail.com.
Gerard MarriottDepartment of Bioengineering, University of California at Berkeley, Berkeley, CA 94720, USA. gmlab@berkeley.edu.
Biao LuDepartment of Bioengineering, Santa Clara University, 500 El Camino Real, Santa Clara, CA 95053, USA. blu2@scu.edu nduong@alumni.scu.edu dhlevy@umd.edu mdo@alumni.scu.edu akbrown@scu.edu zacstickney@gmail.com.ORCID http://orcid.org/0000-0002-0307-9901
Santa Clara University · USBerkeley College · US

Funding

Development of a novel exosome-based enzyme replacement therapy for the treatment of human lysosomal storage disease (LSDs)R15GM137449 · NIGMS · SANTA CLARA UNIVERSITY · PI LU, BIAO · 2020 to 2020
$411k
NIGMS NIH HHS R15 GM137449
6 · The paper itself

Abstract

Exosomes are cell-derived extracellular vesicles that have great potential in the field of nano-medicine. However, a fundamental challenge in the engineering of exosomes is the design of biocompatible molecular scaffolds on their surface to enable cell targeting and therapeutic functions. CD63 is a hallmark protein of natural exosomes that is highly enriched on the external surface of the membrane. We have previously described engineering of CD63 for use as a molecular scaffold in order to introduce cell-targeting features to the exosome surface. Despite this initial success, the restrictive M-shaped topology of full-length CD63 may hinder specific applications that require N- or C-terminal display of cell-targeting moieties on the outer surface of the exosome. In this study, we describe new and topologically distinct CD63 scaffolds that enable robust and flexible surface engineering of exosomes. In particular, we conducted sequential deletions of the transmembrane helix of CD63 to generate a series of CD63 truncates, each genetically-fused to a fluorescent protein. Molecular and cellular characterization studies showed truncates of CD63 harboring the transmembrane helix 3 (TM3) correctly targeted and anchored to the exosome membrane and exhibited distinct n-, N-, Ω-, or I-shaped membrane topologies in the exosomal membrane. We further established that these truncates retained robust membrane-anchoring and exosome-targeting activities when stably expressed in the HEK293 cells. Moreover, HEK293 cells produced engineered exosomes in similar quantities to cells expressing full-length CD63. Based on the results of our systematic sequential deletion studies, we propose a model to understand molecular mechanisms that underlie membrane-anchoring and exosome targeting features of CD63. In summary, we have established new and topologically distinct scaffolds based on engineering of CD63 that enables flexible engineering of the exosome surface for applications in disease-targeted drug delivery and therapy.

Indexed as

ExosomesExtracellular VesiclesHEK293 CellsHumansProteinsProtein TransportTetraspanin 30CD63 protein, humanProteinsTetraspanin 30

Identifiers

PMID32463402
PMCPMC7313400
OpenAlexW3028170824

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.